Skærmbillede 2016-08-01 kl. 19.45.04

BTD til lille ukendt biotek selskab

(opdateret med 10K) Vi initierer en købsanbefaling på et lille biotekselskab der netop har fået Breakthrough Designation af amerikanske FDA og samtidigt clearing på deres design af fase 3 studie. Deres fase 2 studie har vist imponerende data med CR på 42% i combination med stoffet Azacitidine. Og de har mere end fordoblet median overall survival (OS) til 13,3 måneder. Selskabet, …

Read more.

---

Tough love and hand holding

Sådan indleder Scorpio Tankers direktør gårsdagens conference call. Det er usædvanligt og det er også mærkelige tider at investere i. Det er som om markedet er blevet meget optaget af den kortsigtede støj og ikke det langsigtede signal. På både Tanker og Product tanker området er der brand udsalg på snart sagt alle virksomheder så er det tid til at stoppe …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.